Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Preventionmanagement of the global epidemic of obesity. Report of the WHO consultation on obesity (Geneva, June 3-5, 1997).
World Health Organization, (1998),
[2.]
S. Chinn, R.J. Rona.
Prevalence and trends in overweight and obesity in three cross sectional studies of British children.
BMJ, 322 (2001), pp. 24-26
[3.]
J. Aranceta, C. Pérez Rodrigo, L.l. Serra, L. Ribas, J. Quiles, J. Vioque, M. Foz.
Grupo Colaborativo Español para el estudio de la Obesidad. Prevalencia de la obesidad en España: estudio SEEDO 97.
Med Clin (Barc), 111 (1998), pp. 441-445
[4.]
J.F. Meco, X. Pintó, J.M. Escribá, M. Vela, F. Jara, C. Pallarés, et al.
Cardiovascular risk factors associated with clinically isolated and diffuse atherosclerosis in coronary artery disease Spanish patients.
Eur J Clin Invest, 28 (1998), pp. 643-650
[5.]
Euroaspire I and II group..
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries.
Lancet, 357 (2001), pp. 95-1001
[7.]
E. Ros.
Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk.
Atherosclerosis, 151 (2000), pp. 357-379
[8.]
P.C.Y. Tong, Z.S.K. Lee, M. Sea, C.C. Chow, G.T. Ko, W.B. Chan, et al.
The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese chinese subjects with or without type 2 diabetes.
Arch Intern Med, 162 (2002), pp. 2428-3245
[9.]
S.B. Heymsfield, K.R. Segal, J. Hauptman, C.P. Lucas, M.N. Boldrin, A. Rissanen, et al.
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
Arch Intern Med, 160 (2000), pp. 1321-1326
[10.]
F. Lindgarde.
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study.
J Intern Med, 248 (2000), pp. 245-254
[11.]
L. Sjostrom, A. Rissanen, A. Andersen, M. Boldrin, A. Golay, H.P. Koppeschaar, et al.
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.
Lancet, 352 (1998), pp. 167-172
[12.]
J. Zhi, A.T. Melia, R. Guerciolini, J. Chung, J. Kinberg, J.B. Hauptman, I.H. Patel.
Restrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunters.
Clin Pharmacol Ther, 56 (1994), pp. 82-85
[13.]
K.C. Tan, A.W. Tso, R.W. Pang, K.S. Lam.
Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus.
Diabet Med, 19 (2002), pp. 944-948
[14.]
A.S. Wierzbicki, T.M. Reynolds, M.A. Crook.
Usefulness of orlistat in the treatment of severe hypertriglyceridemia.
Am J Cardiol, 89 (2002), pp. 229-231
[15.]
G. Reaven, K. Segal, J. Hauptman, M. Boldrin, C. Lucas.
Effect of Orlistat-Assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
Am J Cardiol, 87 (2001), pp. 827-831
[16.]
J.R. Patsch, G. Miesenbock, T. Hopferwieser, V. Muhlberger, E. Knapp, J.K. Dunn, et al.
The relationship of triglyceride metabolism and coronary artery disease: studies in the postprandial state.
Arterioscler Thromb, 12 (1992), pp. 1184-1190
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.